ArticleTranslational oncology2026
TFF1-mediated suppression of the TCA cycle promotes bone metastasis in triple-negative breast cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by limited treatment options and poor prognosis. While TNBC exhibits a lower incidence of bone metastasis compared to luminal subtypes, its occurrence is associated with substantial morbidity and mortality. The metabolic mechanisms enabling TNBC cells to colonize bone remain largely undefined. In this study, a bone-tropic TNBC subline (MDA-MB-231/BM) was developed through iterative intracardiac inoculation in mice, followed by transcriptomic profiling to identify genes with altered expression. A CRISPR/Cas9 knockout library screen in MDA-MB-231 cells further revealed critical regulators of bone metastasis. Notably, dual-omics analysis demonstrated a consistent downregulation of key enzymes in the tricarboxylic acid (TCA) cycle within bone-metastatic TNBC cells. Functional experiments showed that PDHA1 knockout impaired cell migration, invasion, and mitochondrial respiration, underscoring the TCA cycle's essential role in metastasis. Among the identified regulators, TFF1 emerged as a potent suppressor of TCA cycle gene expression. Deletion of TFF1 enhanced mitochondrial function, reduced metastatic burden in vivo, and extended survival in mouse models. Supporting clinical relevance, TCGA data showed significantly higher TFF1 expression in luminal breast cancer compared to TNBC, aligning with the greater propensity for bone metastasis in luminal subtypes. These findings reveal that TFF1-mediated suppression of the TCA cycle contributes to the metabolic adaptation of TNBC cells for bone colonization, offering a potential therapeutic vulnerability and advocating for subtype-specific metabolic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.